Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.

Abstract: Antagonists at the NMDA receptor complex which are benz b!azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Abstract: Benz[b]azepine compounds, pharmaceutical compositions containing them and methods for the treatment of neurological disorders utilizing them.

Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.

Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.